查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1452672

全球颅内治疗递送市场 - 全球产业分析、规模、占有率、成长、趋势、预测 (2031) - 依治疗、依适应症、依地区

Intracranial Therapeutic Delivery Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region:
出版日期: | 出版商: Fairfield Market Research | 英文 168 Pages | 商品交期: 2-5个工作天内

价格
简介目录

全球颅内治疗服务市场正处于前所未有的成长边缘。 预计到 2024 年，该市场价值将达到 22 亿美元，并预计在未来十年以 9% 的复合年增长率快速增长，到 2031 年将达到惊人的 40 亿美元。 这一激增反映了对神经病学创新治疗的需求不断增长以及全球神经系统疾病盛行率的上升。

颅内治疗递送在 2021 年约占全球再生医学市场的 6.1%，处于病患照护变革的最前线。 这个领域非常重视细胞、基因和酵素替代疗法，为无数疾病的治疗带来了新的曙光，并为传统疗法的不足带来了希望。

从 2018 年到 2023 年，颅内治疗递送方法的受欢迎程度和有效性显着上升，特别是在细胞和基因治疗领域。 这种范式转移得到了包括Bristol Myers Squibb、Gilead Sciences &Company、Xcell Biosciences Inc.在内的生物製药巨头的广泛研究和合作的支持，并强调疾病管理和预防的变革性方法。 透过策略收购和合作，这些领先公司对卓越的追求正在创造新的行业基准。

本报告研究了全球颅内治疗递送市场，并提供了市场概述，包括依治疗、适应症、区域划分的趋势以及进入市场的公司的竞争趋势。

目录

第 1 章执行摘要

第二章市场概述

  • 市场定义与细分
  • 市场动态
  • 价值链分析
  • 波特五力分析
  • 新冠肺炎 (COVID-19) 影响分析
  • 乌克兰和俄罗斯之间衝突的影响
  • 经济概况
  • 杵分析

第 3 章2018-2031 年全球颅内治疗实施市场展望

  • 2018-2031 年全球颅内治疗递送市场前景（依治疗方式、价值（十亿美元））
  • 2018-2031 年全球颅内治疗递送市场展望（依适应症、价值（十亿美元））
  • 2018-2031 年全球颅内治疗递送市场前景（依地区、价值（十亿美元））

第 4 章北美颅内治疗实施市场展望，2018-2031

第五章欧洲颅内治疗实施市场展望，2018-2031

第 6 章亚太地区颅内治疗递送市场展望，2018-2031 年

第 7 章拉丁美洲颅内治疗递送市场展望，2018-2031 年

第 8 章中东和非洲颅内治疗递送市场前景，2018-2031

第九章竞争态势

  • 依治疗方法和适应症划分的热图
  • 2023 年公司市占率分析
  • 竞争力仪表板
  • 公司简介
    • Novartis AG
    • BioMarin
    • CORESTEM Inc.
    • Alaunos Therapeutics, Inc.
    • Apic Bio
    • Stemedica Cell Technologies, Inc.
    • Voyager Therapeutics
    • Bayer AG
    • Abeona Therapeutics
    • Spark Therapeutics

第 10 章附录

简介目录

The global intracranial therapeutic delivery market is poised for unprecedented growth. According to a comprehensive market analysis, the sector, valued at US$ 2.2 billion in 2024, is projected to burgeon at a compound annual growth rate (CAGR) of 9% over the next decade, culminating in a staggering US$ 4 billion by 2031. This surge reflects the increasing demand for innovative treatments in neurology and the rising prevalence of neurological disorders worldwide.

Intracranial Therapeutic Delivery: A Pillar of Regenerative Medicine

Accounting for approximately 6.1% of the global regenerative medicine market in 2021, intracranial therapeutic delivery stands at the forefront of transforming patient care. With a significant emphasis on cell, gene, and enzyme replacement therapies, this sector promises a new dawn in the treatment of a myriad of conditions, offering hope where traditional modalities fall short.

A Decade in Review: Triumphs and Innovations

The period from 2018 to 2023 has witnessed a notable ascent in the popularity and efficacy of intracranial therapeutic delivery methods, especially in the realms of cell and gene therapy. This paradigm shift, underpinned by extensive research and collaboration among biopharmaceutical giants such as Bristol Myers Squibb, Gilead Sciences & Company, and Xcell Biosciences Inc., underscores a transformative approach to disease management and prevention. The pursuit of excellence by these key players, through strategic acquisitions and partnerships, is setting new benchmarks in the industry.

Market Drivers: A Confluence of Innovation and Opportunity

The market's trajectory is notably influenced by the burgeoning pipeline of cell, gene, and enzyme replacement therapies, which account for a substantial portion of the pharmaceutical industry's research focus. With over 750 trials and more than 200 investigational new drug applications anticipated by the U.S. FDA, the sector is on the cusp of delivering groundbreaking treatments to patients across the globe.

Moreover, a tangible shift towards regenerative therapies over conventional drug-based treatments is reshaping the landscape. These advancements, coupled with supportive government policies, especially in emerging economies, herald a new era of healthcare possibilities.

Challenges and Constraints: Navigating Through Uncertainties

Despite the optimistic outlook, the market faces hurdles, primarily due to the high costs associated with these advanced therapies. The financial implications for patients and healthcare systems, along with a lack of comprehensive reimbursement policies, present significant challenges. Addressing these concerns is crucial for ensuring the accessibility and sustainability of intracranial therapeutic delivery methods.

Geographical Insights: Key Markets and Emerging Players

  • United States: Leading the charge with a 36.4% market share, the U.S. is a hotbed for R&D, bolstered by robust government support and regulatory frameworks.
  • Germany: With a quarter share of the European market, Germany's robust healthcare expenditure and thriving biopharmaceutical landscape make it a key player in the sector.
  • United Kingdom: The U.K.'s commitment to regenerative medicine and its significant contribution to the European advanced therapeutic medicinal products (ATMP) sector underscore its pivotal role in the market's growth.
  • South Korea: Demonstrating rapid progress, South Korea's strategic investments in biopharma and biotech are unlocking new possibilities in intracranial therapeutic delivery.

The Competitive Landscape: Fostering Innovation and Collaboration

The market's future is shaped by strategic collaborations, mergers, and acquisitions among leading firms. Innovations and product launches are critical for maintaining competitive advantage and addressing the evolving needs of patients worldwide. Notable developments, such as ElevateBio's lentiviral vector production platform and the collaboration between Biogen and Ginkgo Bioworks, highlight the industry's commitment to revolutionizing intracranial therapeutic delivery.

Key Companies Profiled

  • Novartis AG
  • BioMarin
  • CORESTEM Inc.
  • Alaunos Therapeutics, Inc.
  • Apic Bio
  • Stemedica Cell Technologies, Inc.
  • Voyager Therapeutics
  • Bayer AG
  • Abeona Therapeutics
  • Spark Therapeutics

Segmentation of Intracranial Therapeutic Delivery Industry

Intracranial Therapeutic Delivery Market by Therapy:

  • Cell-based Therapy
  • Gene Therapy
  • Enzyme Replacement Therapy

Intracranial Therapeutic Delivery Market by Indication:

  • Spinal Muscular Atrophy (SMA)
  • Multiple Sclerosis
  • Batten Disease
  • Amyotrophic Lateral Sclerosis

Intracranial Therapeutic Delivery Market by Region:

  • U.S. Intracranial Therapeutic Delivery Market
  • Europe Intracranial Therapeutic Delivery Market
  • Rest of the World (ROW) Intracranial Therapeutic Delivery Market

Table of Contents

1. Executive Summary

  • 1.1. Global Intracranial Therapeutic Delivery Market Snapshot
  • 1.2. Future Projections
  • 1.3. Key Market Trends
  • 1.4. Regional Snapshot, by Value, 2023
  • 1.5. Analyst Recommendations

2. Market Overview

  • 2.1. Market Definitions and Segmentations
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Market Opportunities
  • 2.3. Value Chain Analysis
  • 2.4. Porter's Five Forces Analysis
  • 2.5. COVID-19 Impact Analysis
    • 2.5.1. Supply
    • 2.5.2. Demand
  • 2.6. Impact of Ukraine-Russia Conflict
  • 2.7. Economic Overview
    • 2.7.1. World Economic Projections
  • 2.8. PESTLE Analysis

3. Global Intracranial Therapeutic Delivery Market Outlook, 2018 - 2031

  • 3.1. Global Intracranial Therapeutic Delivery Market Outlook, by Therapy, Value (US$ Bn), 2018 - 2031
    • 3.1.1. Key Highlights
      • 3.1.1.1. Cell-based Therapy
      • 3.1.1.2. Gene Therapy
      • 3.1.1.3. Enzyme Replacement Therapy
  • 3.2. Global Intracranial Therapeutic Delivery Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
    • 3.2.1. Key Highlights
      • 3.2.1.1. Spinal Muscular Atrophy (SMA)
      • 3.2.1.2. Multiple Sclerosis
      • 3.2.1.3. Batten Disease
      • 3.2.1.4. Amyotrophic Lateral Sclerosis
  • 3.3. Global Intracranial Therapeutic Delivery Market Outlook, by Region, Value (US$ Bn), 2018 - 2031
    • 3.3.1. Key Highlights
      • 3.3.1.1. North America
      • 3.3.1.2. Europe
      • 3.3.1.3. Asia Pacific
      • 3.3.1.4. Latin America
      • 3.3.1.5. Middle East & Africa

4. North America Intracranial Therapeutic Delivery Market Outlook, 2018 - 2031

  • 4.1. North America Intracranial Therapeutic Delivery Market Outlook, by Therapy, Value (US$ Bn), 2018 - 2031
    • 4.1.1. Key Highlights
      • 4.1.1.1. Cell-based Therapy
      • 4.1.1.2. Gene Therapy
      • 4.1.1.3. Enzyme Replacement Therapy
  • 4.2. North America Intracranial Therapeutic Delivery Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
    • 4.2.1. Key Highlights
      • 4.2.1.1. Spinal Muscular Atrophy (SMA)
      • 4.2.1.2. Multiple Sclerosis
      • 4.2.1.3. Batten Disease
      • 4.2.1.4. Amyotrophic Lateral Sclerosis
  • 4.3. North America Intracranial Therapeutic Delivery Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 4.3.1. Key Highlights
      • 4.3.1.1. U.S. Intracranial Therapeutic Delivery Market by Therapy, Value (US$ Bn), 2018 - 2031
      • 4.3.1.2. U.S. Intracranial Therapeutic Delivery Market by Indication, Value (US$ Bn), 2018 - 2031
      • 4.3.1.3. Canada Intracranial Therapeutic Delivery Market by Therapy, Value (US$ Bn), 2018 - 2031
      • 4.3.1.4. Canada Intracranial Therapeutic Delivery Market by Indication, Value (US$ Bn), 2018 - 2031
    • 4.3.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Intracranial Therapeutic Delivery Market Outlook, 2018 - 2031

  • 5.1. Europe Intracranial Therapeutic Delivery Market Outlook, by Therapy, Value (US$ Bn), 2018 - 2031
    • 5.1.1. Key Highlights
      • 5.1.1.1. Cell-based Therapy
      • 5.1.1.2. Gene Therapy
      • 5.1.1.3. Enzyme Replacement Therapy
  • 5.2. Europe Intracranial Therapeutic Delivery Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
    • 5.2.1. Key Highlights
      • 5.2.1.1. Spinal Muscular Atrophy (SMA)
      • 5.2.1.2. Multiple Sclerosis
      • 5.2.1.3. Batten Disease
      • 5.2.1.4. Amyotrophic Lateral Sclerosis
    • 5.2.2. BPS Analysis/Market Attractiveness Analysis
  • 5.3. Europe Intracranial Therapeutic Delivery Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 5.3.1. Key Highlights
      • 5.3.1.1. Germany Intracranial Therapeutic Delivery Market by Therapy, Value (US$ Bn), 2018 - 2031
      • 5.3.1.2. Germany Intracranial Therapeutic Delivery Market by Indication, Value (US$ Bn), 2018 - 2031
      • 5.3.1.3. U.K. Intracranial Therapeutic Delivery Market by Therapy, Value (US$ Bn), 2018 - 2031
      • 5.3.1.4. U.K. Intracranial Therapeutic Delivery Market by Indication, Value (US$ Bn), 2018 - 2031
      • 5.3.1.5. France Intracranial Therapeutic Delivery Market by Therapy, Value (US$ Bn), 2018 - 2031
      • 5.3.1.6. France Intracranial Therapeutic Delivery Market by Indication, Value (US$ Bn), 2018 - 2031
      • 5.3.1.7. Italy Intracranial Therapeutic Delivery Market by Therapy, Value (US$Bn), 2018 - 2031
      • 5.3.1.8. Italy Intracranial Therapeutic Delivery Market by Indication, Value (US$Bn), 2018 - 2031
      • 5.3.1.9. Turkey Intracranial Therapeutic Delivery Market by Therapy, Value (US$ Bn), 2018 - 2031
      • 5.3.1.10. Turkey Intracranial Therapeutic Delivery Market by Indication, Value (US$ Bn), 2018 - 2031
      • 5.3.1.11. Russia Intracranial Therapeutic Delivery Market by Therapy, Value (US$ Bn), 2018 - 2031
      • 5.3.1.12. Russia Intracranial Therapeutic Delivery Market by Indication, Value (US$ Bn), 2018 - 2031
      • 5.3.1.13. Rest of Europe Intracranial Therapeutic Delivery Market by Therapy, Value (US$ Bn), 2018 - 2031
      • 5.3.1.14. Rest of Europe Intracranial Therapeutic Delivery Market by Indication, Value (US$ Bn), 2018 - 2031
    • 5.3.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Intracranial Therapeutic Delivery Market Outlook, 2018 - 2031

  • 6.1. Asia Pacific Intracranial Therapeutic Delivery Market Outlook, by Therapy, Value (US$ Bn), 2018 - 2031
    • 6.1.1. Key Highlights
      • 6.1.1.1. Cell-based Therapy
      • 6.1.1.2. Gene Therapy
      • 6.1.1.3. Enzyme Replacement Therapy
  • 6.2. Asia Pacific Intracranial Therapeutic Delivery Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
    • 6.2.1. Key Highlights
      • 6.2.1.1. Spinal Muscular Atrophy (SMA)
      • 6.2.1.2. Multiple Sclerosis
      • 6.2.1.3. Batten Disease
      • 6.2.1.4. Amyotrophic Lateral Sclerosis
    • 6.2.2. Others BPS Analysis/Market Attractiveness Analysis
  • 6.3. Asia Pacific Intracranial Therapeutic Delivery Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 6.3.1. Key Highlights
      • 6.3.1.1. China Intracranial Therapeutic Delivery Market by Therapy, Value (US$Bn), 2018 - 2031
      • 6.3.1.2. China Intracranial Therapeutic Delivery Market by Indication, Value (US$ Bn), 2018 - 2031
      • 6.3.1.3. Japan Intracranial Therapeutic Delivery Market by Therapy, Value (US$ Bn), 2018 - 2031
      • 6.3.1.4. Japan Intracranial Therapeutic Delivery Market by Indication, Value (US$ Bn), 2018 - 2031
      • 6.3.1.5. South Korea Intracranial Therapeutic Delivery Market by Therapy, Value (US$ Bn), 2018 - 2031
      • 6.3.1.6. South Korea Intracranial Therapeutic Delivery Market by Indication, Value (US$ Bn), 2018 - 2031
      • 6.3.1.7. India Intracranial Therapeutic Delivery Market by Therapy, Value (US$ Bn), 2018 - 2031
      • 6.3.1.8. India Intracranial Therapeutic Delivery Market by Indication, Value (US$ Bn), 2018 - 2031
      • 6.3.1.9. Southeast Asia Intracranial Therapeutic Delivery Market by Therapy, Value (US$ Bn), 2018 - 2031
      • 6.3.1.10. Southeast Asia Intracranial Therapeutic Delivery Market by Indication, Value (US$ Bn), 2018 - 2031
      • 6.3.1.11. Rest of Asia Pacific Intracranial Therapeutic Delivery Market by Therapy, Value (US$ Bn), 2018 - 2031
      • 6.3.1.12. Rest of Asia Pacific Intracranial Therapeutic Delivery Market by Indication, Value (US$ Bn), 2018 - 2031
    • 6.3.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Intracranial Therapeutic Delivery Market Outlook, 2018 - 2031

  • 7.1. Latin America Intracranial Therapeutic Delivery Market Outlook, by Therapy, Value (US$ Bn), 2018 - 2031
    • 7.1.1. Key Highlights
      • 7.1.1.1. Cell-based Therapy
      • 7.1.1.2. Gene Therapy
      • 7.1.1.3. Enzyme Replacement Therapy
  • 7.2. Latin America Intracranial Therapeutic Delivery Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
    • 7.2.1. Key Highlights
      • 7.2.1.1. Spinal Muscular Atrophy (SMA)
      • 7.2.1.2. Multiple Sclerosis
      • 7.2.1.3. Batten Disease
      • 7.2.1.4. Amyotrophic Lateral Sclerosis
    • 7.2.2. BPS Analysis/Market Attractiveness Analysis
  • 7.3. Latin America Intracranial Therapeutic Delivery Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 7.3.1. Key Highlights
      • 7.3.1.1. Brazil Intracranial Therapeutic Delivery Market by Therapy, Value (US$ Bn), 2018 - 2031
      • 7.3.1.2. Brazil Intracranial Therapeutic Delivery Market by Indication, Value (US$ Bn), 2018 - 2031
      • 7.3.1.3. Mexico Intracranial Therapeutic Delivery Market by Therapy, Value (US$ Bn), 2018 - 2031
      • 7.3.1.4. Mexico Intracranial Therapeutic Delivery Market by Indication, Value (US$ Bn), 2018 - 2031
      • 7.3.1.5. Argentina Intracranial Therapeutic Delivery Market by Therapy, Value (US$ Bn), 2018 - 2031
      • 7.3.1.6. Argentina Intracranial Therapeutic Delivery Market by Indication, Value (US$ Bn), 2018 - 2031
      • 7.3.1.7. Rest of Latin America Intracranial Therapeutic Delivery Market by Therapy, Value (US$ Bn), 2018 - 2031
      • 7.3.1.8. Rest of Latin America Intracranial Therapeutic Delivery Market by Indication, Value (US$ Bn), 2018 - 2031
    • 7.3.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Intracranial Therapeutic Delivery Market Outlook, 2018 - 2031

  • 8.1. Middle East & Africa Intracranial Therapeutic Delivery Market Outlook, by Therapy, Value (US$ Bn), 2018 - 2031
    • 8.1.1. Key Highlights
      • 8.1.1.1. Cell-based Therapy
      • 8.1.1.2. Gene Therapy
      • 8.1.1.3. Enzyme Replacement Therapy
  • 8.2. Middle East & Africa Intracranial Therapeutic Delivery Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
    • 8.2.1. Key Highlights
      • 8.2.1.1. Spinal Muscular Atrophy (SMA)
      • 8.2.1.2. Multiple Sclerosis
      • 8.2.1.3. Batten Disease
      • 8.2.1.4. Amyotrophic Lateral Sclerosis
    • 8.2.2. BPS Analysis/Market Attractiveness Analysis
  • 8.3. Middle East & Africa Intracranial Therapeutic Delivery Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 8.3.1. Key Highlights
      • 8.3.1.1. GCC Intracranial Therapeutic Delivery Market by Therapy, Value (US$ Bn), 2018 - 2031
      • 8.3.1.2. GCC Intracranial Therapeutic Delivery Market by Indication, Value (US$ Bn), 2018 - 2031
      • 8.3.1.3. South Africa Intracranial Therapeutic Delivery Market by Therapy, Value (US$ Bn), 2018 - 2031
      • 8.3.1.4. South Africa Intracranial Therapeutic Delivery Market by Indication, Value (US$ Bn), 2018 - 2031
      • 8.3.1.5. Egypt Intracranial Therapeutic Delivery Market by Therapy, Value (US$ Bn), 2018 - 2031
      • 8.3.1.6. Egypt Intracranial Therapeutic Delivery Market by Indication, Value (US$ Bn), 2018 - 2031
      • 8.3.1.7. Nigeria Intracranial Therapeutic Delivery Market by Therapy, Value (US$ Bn), 2018 - 2031
      • 8.3.1.8. Nigeria Intracranial Therapeutic Delivery Market by Indication, Value (US$ Bn), 2018 - 2031
      • 8.3.1.9. Rest of Middle East & Africa Intracranial Therapeutic Delivery Market by Therapy, Value (US$ Bn), 2018 - 2031
      • 8.3.1.10. Rest of Middle East & Africa Intracranial Therapeutic Delivery Market by Indication, Value (US$ Bn), 2018 - 2031
    • 8.3.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

  • 9.1. Therapy vs by Indication Heatmap
  • 9.2. Company Market Share Analysis, 2023
  • 9.3. Competitive Dashboard
  • 9.4. Company Profiles
    • 9.4.1. Novartis AG
      • 9.4.1.1. Company Overview
      • 9.4.1.2. Product Portfolio
      • 9.4.1.3. Financial Overview
      • 9.4.1.4. Business Strategies and Development
    • 9.4.2. BioMarin
      • 9.4.2.1. Company Overview
      • 9.4.2.2. Product Portfolio
      • 9.4.2.3. Financial Overview
      • 9.4.2.4. Business Strategies and Development
    • 9.4.3. CORESTEM Inc.
      • 9.4.3.1. Company Overview
      • 9.4.3.2. Product Portfolio
      • 9.4.3.3. Financial Overview
      • 9.4.3.4. Business Strategies and Development
    • 9.4.4. Alaunos Therapeutics, Inc.
      • 9.4.4.1. Company Overview
      • 9.4.4.2. Product Portfolio
      • 9.4.4.3. Financial Overview
      • 9.4.4.4. Business Strategies and Development
    • 9.4.5. Apic Bio
      • 9.4.5.1. Company Overview
      • 9.4.5.2. Product Portfolio
      • 9.4.5.3. Financial Overview
      • 9.4.5.4. Business Strategies and Development
    • 9.4.6. Stemedica Cell Technologies, Inc.
      • 9.4.6.1. Company Overview
      • 9.4.6.2. Product Portfolio
      • 9.4.6.3. Financial Overview
      • 9.4.6.4. Business Strategies and Development
    • 9.4.7. Voyager Therapeutics
      • 9.4.7.1. Company Overview
      • 9.4.7.2. Product Portfolio
      • 9.4.7.3. Financial Overview
      • 9.4.7.4. Business Strategies and Development
    • 9.4.8. Bayer AG
      • 9.4.8.1. Company Overview
      • 9.4.8.2. Product Portfolio
      • 9.4.8.3. Financial Overview
      • 9.4.8.4. Business Strategies and Development
    • 9.4.9. Abeona Therapeutics
      • 9.4.9.1. Company Overview
      • 9.4.9.2. Product Portfolio
      • 9.4.9.3. Financial Overview
      • 9.4.9.4. Business Strategies and Development
    • 9.4.10. Spark Therapeutics
      • 9.4.10.1. Company Overview
      • 9.4.10.2. Product Portfolio
      • 9.4.10.3. Financial Overview
      • 9.4.10.4. Business Strategies and Development

10. Appendix

  • 10.1. Research Methodology
  • 10.2. Report Assumptions
  • 10.3. Acronyms and Abbreviations

List of Region/Countries

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Turkey
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • South Korea
    • India
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa